T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Garcia Centeno R, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJCMM, Delemer B, Petit JM, Schoefl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Book Volume: 23

Pages Range: 871-881

Journal Issue: 11

DOI: 10.1530/ERC-16-0356

Abstract

GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyper-intense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypo-intense adenomas had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyper-intense groups (P < 0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypo-intense group (38%) compared with the T2-iso- and hyper-intense groups (8% and 3%, respectively; P < 0.0001). The response to SSA correlated with the calculated T2 intensity: the lower the T2-weighted intensity, the greater the decrease in random GH (P < 0.0001, r = 0.22), IGF-1 (P < 0.0001, r = 0.14) and adenoma volume (P < 0.0001, r = 0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly.

Involved external institutions

University of L'Aquila / Università degli Studi dell'Aquila Italy (IT) Université libre de Bruxelles (ULB) / Free University of Brussels Belgium (BE) Assistance Publique Hopitaux de Marseille France (FR) Centre hospitalier régional et universitaire de Besançon (CHRU Besancon) France (FR) Université Catholique de Louvain (UCL) Belgium (BE) University of Liège (ULg) / Université de Liège Belgium (BE) Centre hospitalier universitaire (CHU) d'Angers France (FR) Hôpitaux universitaires de Strasbourg (HUS) / University Hospital Strasbourg France (FR) Hospices Civils de Lyon (CHU) France (FR) Klinikum Bamberg Germany (DE) Centre hospitalier universitaire (CHU) de Dijon Bourgogne France (FR) Centre hospitalier universitaire de Reims (CHU de Reims) France (FR) Erasmus University Rotterdam (EUR) / Erasmus Universiteit Rotterdam Netherlands (NL) University of Genova / Università degli Studi di Genova Italy (IT) Centre Pierre-et-Marie-Curie Algeria (DZ) Kazan State Medical University (KSMU) Russian Federation (RU) Moscow Regional Research and Clinical Institute (MONIKI) Russian Federation (RU) Centre Hospitalier Universitaire de Nancy / CHU Hôpitaux de Brabois France (FR) Univerzita Karlova v Praze / Charles University in Prague Czech Republic (CZ) Centre Hospitalier Universitaire de Bordeaux / CHU Bordeaux France (FR) Hospital de la Santa Creu i Sant Pau Spain (ES) Hospital General Universitario Gregorio Marañón Spain (ES) Erciyes University / Erciyes Üniversitesi Turkey (TR)

How to cite

APA:

Potorac, I., Petrossians, P., Daly, A.F., Alexopoulou, O., Borot, S., Sahnoun-Fathallah, M.,... Beckers, A. (2016). T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer, 23(11), 871-881. https://dx.doi.org/10.1530/ERC-16-0356

MLA:

Potorac, Iulia, et al. "T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly." Endocrine-Related Cancer 23.11 (2016): 871-881.

BibTeX: Download